Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Research & Development data on file, last reported at $430895.0 in Q1 2026.

• On a quarterly basis, Research & Development fell 95.9% year-over-year to $430895.0 in Q1 2026; TTM through Mar 2026 was $12.1 million, a 51.48% decrease from a year earlier, with the FY2025 full-year figure at $29.8 million, up 73.11% from the prior year.
• Research & Development for Q1 2026 stood at $430895.0, down from $6.4 million in the prior quarter.
• Over the last five years, Research & Development for IKT reached as high as $13.6 million in Q4 2023 and fell as low as $55114.0 in Q3 2025.
• Historically, Research & Development has averaged $4.5 million across 5 years, with a median of $3.1 million in 2024.
• Across the five-year window, Research & Development surged 344.91% in 2023 and plunged 98.68% in 2025, its largest moves.
• Year by year, Research & Development stood at $3.1 million in 2022, then soared by 344.91% to $13.6 million in 2023, then slumped by 47.06% to $7.2 million in 2024, then decreased by 11.6% to $6.4 million in 2025, then sank by 93.22% to $430895.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $430895.0 in Q1 2026, $6.4 million in Q4 2025, and $55114.0 in Q3 2025.